Martha is slated to be replaced in the chief integration officer role by Bill Burke, who joined Medtronic as part of its $50 billion acquisition of Covidien early this year.
“Chris has passionately served Medtronic for the past 21 years in various leadership roles.I know I speak for all of Medtronic’s employees in wishing him the best in this new phase of his career,” chairman & CEO Omar Ishrak said in prepared remarks. “We are pleased to name Geoff Martha as the new leader for the restorative therapies group. In his time at Medtronic, Geoff has demonstrated his leadership capacity in architecting and driving our three-pillared global strategy around new therapies, economic value and globalization, as well as leading our effort to acquire and integrate Covidien, the largest acquisition in Medtronic’s history. I know Geoff will provide innovative and effective leadership for the RTG team as we continue to expand and grow our impact for those people around the world who could benefit from our restorative therapies.”
“I’m excited to lead this innovative group of Medtronic professionals who are committed to ensuring that we provide physicians and patients the technologies and services that will allow people with chronic diseases to live their lives to the fullest,” Martha added. “I particularly look forward to partnering with customers around the world to ensure we are delivering solutions that meaningfully impact their practices and the patients they serve. Medtronic has a tremendous capacity to innovate, and I’m looking forward to leading this team to spur new levels of ingenuity, growth and performance.”
Martha is slated to be replaced in the chief integration officer role by his deputy, Bill Burke, who joined Medtronic as part of its $50 billion acquisition of Covidien early this year.
“No one is more prepared to step into this role than Bill Burke,” Ishrak said. “His background and knowledge as a leader within Covidien up to and through the acquisition and his demonstrated leadership presence and actions on the integration thus far make him the ideal choice to lead this critical effort.”
Second Sight Medical names ex-Volcano exec McGuire as CEO
Second Sight Medical (NSDQ:EYES) said it named former Volcano executive Will McGuire to be its new CEO, moving former chief Dr. Robert Greenberg to the chairman’s seat and making Dr. Alfred Mann chairman emeritus.
New HART CEO is Genzyme vet McGorry
Harvard Apparatus Regenerative Technology (NSDQ:HART) said today that it named former Genzyme (NSDQ:GENZ) executive James McGorry to be its new CEO. In April, former chairman, president & CEO David Green agreed to bow out but remain on the board as the company sought a leader with experience in clinical trials and product launches.
TissueGen taps Seifert for spinal cord injury program
TissueGen said it named Jennifer Seifert as its senior scientist, charged with leading the application of its Elute fiber drug-delivery technology to treat spinal cord injuries.